人肝癌細胞HepaRG

細胞名稱

人肝癌細胞HepaRG

貨物編碼

BFN60808919

產品規格

T25培養瓶x1

1.5ml凍存管x2

細胞數量

1x10^6

1x10^6

保存溫度

37℃

-198℃

運輸方式

常溫保溫運輸

干冰運輸

安全等級

1

用途限制

僅供科研   2類

培養體系

90%DMEM+10%FBS+1%三抗

培養溫度

37℃

二氧化碳濃度

5%

簡介

人肝癌細胞HepaRG取自女性供體，貼壁培養。

注釋

Registration: International Depositary Authority, Pasteur Institute Collection Nationale de Cultures de Micro-organismes (CNCM); I-2652.

Characteristics: Can be induced to differentiate into hepatocyte-like cells by exposure to DMSO.

Characteristics: Cell line main applications are sugar and lipid metabolism, physiopathology; drug metabolism and toxicology and viral infection.

Omics: Deep proteome analysis.

Omics: Membrane proteome analysis.

Omics: miRNA expression profiling.

Omics: Transcriptome analysis.

Anecdotal: The 'RG' in the cell name stands for Rumin and Gripon, the two scientists that were influential in the establishment of this cell line.

基因突變

/

HLA信息

/

STR信息

/

參考文獻

PubMed=12432097; DOI=10.1073/pnas.232137699

Gripon P., Rumin S., Urban S., Le Seyec J., Glaise D., Cannie I., Guyomard C., Lucas J., Trepo C., Guguen-Guillouzo C.

Infection of a human hepatoma cell line by hepatitis B virus.

Proc. Natl. Acad. Sci. U.S.A. 99:15655-15660(2002)

PubMed=17241619; DOI=10.1016/j.cbi.2006.12.003

Guillouzo A., Corlu A., Aninat C., Glaise D., Morel F., Guguen-Guillouzo C.

The human hepatoma HepaRG cells: a highly differentiated model for studies of liver metabolism and toxicity of xenobiotics.

Chem. Biol. Interact. 168:66-73(2007)

PubMed=17393521; DOI=10.1002/hep.21536

Cerec V., Glaise D., Garnier D., Morosan S., Turlin B., Drenou B., Gripon P., Kremsdorf D., Guguen-Guillouzo C., Corlu A.

Transdifferentiation of hepatocyte-like cells from the human hepatoma HepaRG cell line through bipotent progenitor.

Hepatology 45:957-967(2007)

Patent=US7456018

Gripon P., Guguen-Guillouzo C., Trepo C., Rumin S.

Human hepatoma lines, methods for obtaining same and uses thereof.

Patent number US7456018, 25-Nov-2008

PubMed=20228232; DOI=10.1124/dmd.109.031831

Hart S.N., Li Y., Nakamoto K., Subileau E.-A., Steen D., Zhong X.-B.

A comparison of whole genome gene expression profiles of HepaRG cells and HepG2 cells to primary human hepatocytes and human liver tissues.

Drug Metab. Dispos. 38:988-994(2010)

PubMed=20645056; DOI=10.1007/978-1-60761-688-7_13

Marion M.-J., Hantz O., Durantel D.

The HepaRG cell line: biological properties and relevance as a tool for cell biology, drug metabolism, and virology studies.

Methods Mol. Biol. 640:261-272(2010)

PubMed=21414303; DOI=10.1016/j.bcp.2011.03.004

Ceelen L., De Spiegelaere W., David M., De Craene J., Vinken M., Vanhaecke T., Rogiers V.

Critical selection of reliable reference genes for gene expression study in the HepaRG cell line.

Biochem. Pharmacol. 81:1255-1261(2011)

PubMed=22568886; DOI=10.1517/17425255.2012.685159

Andersson T.B., Kanebratt K.P., Kenna J.G.

The HepaRG cell line: a unique in vitro tool for understanding drug metabolism and toxicology in human.

Expert Opin. Drug Metab. Toxicol. 8:909-920(2012)

PubMed=22594799; DOI=10.3109/13813455.2012.683442

Samanez C.H., Caron S., Briand O., Dehondt H., Duplan I., Kuipers F., Hennuyer N., Clavey V., Staels B.

The human hepatocyte cell lines IHH and HepaRG: models to study glucose, lipid and lipoprotein metabolism.

Arch. Physiol. Biochem. 118:102-111(2012)

PubMed=22643240; DOI=10.1016/j.tiv.2012.05.008

Antherieu S., Chesne C., Li R., Guguen-Guillouzo C., Guillouzo A.

Optimization of the HepaRG cell model for drug metabolism and toxicity studies.

Toxicol. In Vitro 26:1278-1285(2012)

PubMed=22857383; DOI=10.1186/1477-5956-10-47

Sokolowska I., Dorobantu C., Woods A.G., Macovei A., Branza-Nichita N., Darie C.C.

Proteomic analysis of plasma membranes isolated from undifferentiated and differentiated HepaRG cells.

Proteome Sci. 10:47-47(2012)

PubMed=23887712; DOI=10.1038/ncomms3218

Nault J.-C., Mallet M., Pilati C., Calderaro J., Bioulac-Sage P., Laurent C., Laurent A., Cherqui D., Balabaud C., Zucman-Rossi J.

High frequency of telomerase reverse-transcriptase promoter somatic mutations in hepatocellular carcinoma and preneoplastic lesions.

Nat. Commun. 4:2218-2218(2013)

PubMed=26160117; DOI=10.1093/toxsciv136

Sison-Young R.L.C., Mitsa D., Jenkins R.E., Mottram D., Alexandre E., Richert L., Aerts H., Weaver R.J., Jones R.P., Johann E., Hewitt P.G., Ingelman-Sundberg M., Goldring C.E.P., Kitteringham N.R., Park B.K.

Comparative proteomic characterization of 4 human liver-derived single cell culture models reveals significant variation in the capacity for drug disposition, bioactivation, and detoxication.

Toxicol. Sci. 147:412-424(2015)

PubMed=26694163; DOI=10.1371/journal.pone.0144924

Janiszewska J., Szaumkessel M., Kostrzewska-Poczekaj M., Bednarek K., Paczkowska J., Jackowska J., Grenman R., Szyfter K., Wierzbicka M., Giefing M., Jarmuz-Szymczak M.

Global miRNA expression profiling identifies miR-1290 as novel potential oncomiR in laryngeal carcinoma.

PLoS ONE 10:E0144924-E0144924(2015)

PubMed=27169750; DOI=10.1038ep24709

Sharanek A., Burban A., Burbank M., Le Guevel R., Li R., Guillouzo A., Guguen-Guillouzo C.

Rho-kinase/myosin light chain kinase pathway plays a key role in the impairment of bile canaliculi dynamics induced by cholestatic drugs.

Sci. Rep. 6:24709-24709(2016)

PubMed=27780834; DOI=10.1124/dmd.116.072603

van der Mark V.A., de Waart D.R., Shevchenko V., Oude Elferink R.P.J., Chamuleau R.A.F.M., Hoekstra R.

Stable overexpression of the constitutive androstane receptor reduces the requirement for culture with dimethyl sulfoxide for high drug metabolism in HepaRG cells.

Drug Metab. Dispos. 45:56-67(2017)

PubMed=27975304; DOI=10.1007/978-1-4939-6700-1_2

Ni Y., Urban S.

Hepatitis B virus infection of HepaRG cells, HepaRG-hNTCP cells, and primary human hepatocytes.

Methods Mol. Biol. 1540:15-25(2017)

PubMed=28904299; DOI=10.2131/jts.42.641

Tomida T., Ishimura M., Iwaki M.

A cell-based assay using HepaRG cells for predicting drug-induced phospholipidosis.

J. Toxicol. Sci. 42:641-650(2017)